机构:[1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China四川大学华西医院[2]West China School of Medicine, Sichuan University, Chengdu, People’s Republic of China四川大学华西医院[3]Department of Pharmacology, West China School of Basic Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan, People’s Republic of China[4]Department of Anesthesiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, People’s Republic of China四川省人民医院四川省肿瘤医院
Background: Hepatic artery interventional therapy has been recognized as the first choice for advanced liver cancer. However, reliable prognostic markers are still lacking. In the present study, we aimed to evaluate the prognostic value of inflammation factors including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and monocyte to lymphocyte ratio (MLR) in hepatocellular carcinoma (HCC) patients with hepatic artery interventional treatments. Methods: Patients undergoing hepatic artery interventional therapy after being diagnosed with HCC between 2007 and 2014 were enrolled. Pre-treatment NLR, PLR and MLR were calculated, and all factors including gender, age, TNM stage, BCLC staging, inflammation factors, LDH, ALP, CEA, AFP, hepatitis, liver cirrhosis, portal vein involvement, surgical history and hepatic artery interventional treatment on overall survival (OS) were evaluated by the univariate and multivariate Cox proportional hazards analyses. Results: Overall, 407 patients were included. The optimal cutoff values determined by receiver operating characteristic (ROC) curve analyses for NLR, PLR and MLR were 3.82, 140.00 and 0.27, respectively. High NLR was associated with worse OS (median survival time: high NLR group 9 vs low NLR group 19 months, HR 1.842, 95% CI: 1.457-2.329, P<0.001). Elevated PLR was negatively correlated with OS (8 vs 18 months, HR 1.677, 95% CI: 1.302-2.161, P<0.001). Patients in high MLR group had a worse OS (10 vs 21 months, HR 1.626, 95% CI: 1.291-2.048, P<0.001). In multivariate analysis, NLR, LDH, ALP and portal vein involvement were independent prognostic factors for OS of HCC patients after hepatic artery interventional therapy. In addition, for patients in BCLC stage A and B, higher NLR, PLR and MLR were all significantly negatively correlated to median survival time (NLR: 17 vs 26 months, HR: 1.739 (95% CI: 1.279-2.365), P<0.001; PLR: 18 vs 26 months, HR: 1.681 (95% CI: 1.245-2.271), P=0.001; MLR: 20 vs 26 months, HR: 1.589 (95% CI: 1.185-2.129), P=0.002). Conclusion: Elevated pre-treatment NLR, PLR and MLR were associated with worse survival time in HCC patients after hepatic artery interventional therapy. Among them, NLR was an independent prognostic factor for OS.
第一作者机构:[1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China[2]West China School of Medicine, Sichuan University, Chengdu, People’s Republic of China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China[*1]Department of Biotherapy, Cancer Center West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan 610041, People’s Republic of China
推荐引用方式(GB/T 7714):
Linghong Guo,Honghong Ren,Lutong Pu,et al.The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study[J].CANCER MANAGEMENT AND RESEARCH.2020,12:7173-7188.doi:10.2147/CMAR.S257934.
APA:
Linghong Guo,Honghong Ren,Lutong Pu,Xingyu Zhu,Yin Liu&Xuelei Ma.(2020).The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study.CANCER MANAGEMENT AND RESEARCH,12,
MLA:
Linghong Guo,et al."The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study".CANCER MANAGEMENT AND RESEARCH 12.(2020):7173-7188